- Home
- OLN vs TRVI Comparison
OLN vs TRVI Comparison
Compare OLN & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OLN | TRVI |
|---|---|---|
| Founded | 1892 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1994 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OLN | TRVI |
|---|---|---|
| Price | $17.46 | $16.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 11 |
| Target Price | ★ $25.23 | $21.55 |
| AVG Volume (30 Days) | ★ 2.5M | 1.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.92% | N/A |
| EPS Growth | N/A | ★ 31.91 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,780,800,000.00 | N/A |
| Revenue This Year | $2.57 | N/A |
| Revenue Next Year | $3.51 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 3.68 | N/A |
| 52 Week Low | $16.73 | $7.65 |
| 52 Week High | $30.46 | $20.22 |
Technical Indicators
Market Signals| Indicator | OLN | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 39.38 |
| Support Level | N/A | $16.16 |
| Resistance Level | $19.39 | $19.30 |
| Average True Range (ATR) | 0.64 | 0.72 |
| MACD | 0.13 | -0.13 |
| Stochastic Oscillator | 38.53 | 17.86 |
Price Performance
Historical ComparisonAbout OLN Olin Corporation
Olin was founded in 1892 and has been publicly listed since 1917. The company has a unique dual identity compared with some of its chemical peers: it is the world's largest chlor-alkali producer by capacity, and it owns the Winchester brand, a leading US ammunition manufacturer. Olin has three reportable segments: chlor-alkali products and vinyls (CAPV or CAP), Epoxies, and Winchester, which represent around 55%, 20%, and 25% of sales, respectively.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.